TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Lapatinib and Trastuzumab With or Without Endocrine Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients must be female.~* Signed informed consent.~* Locally advanced breast cancers or primary breast cancers are eligible. Locally advanced cancers must be of clinical and/or radiologic size \>3 cm, or \>2 cm with clinical evidence of axillary nodal involvement. (If tumors are less than 3 cm, we will use radiologically measured tumor size to determine the minimal tumor size for eligibility and in assessing tumor size during follow-up).~* HER2 overexpressing tumors defined as HercepTest score of 3+, or \> 10% cells moderately or strongly HER2 positive by other methods, or Allred semi-quantitative score of \>5, or gene amplified.~* Negative serum pregnancy test (HCG) within 7 days of starting study, if of child-bearing potential.~* Kidney and liver function tests - all within 1.5 times the institution's upper limit of normal.~* Performance status (WHO scale) less than 2 and life expectancy more than 6 months.~* Age at least 18 years.~* No brain or leptomeningeal disease.~* No previous or current malignancies at other sites within the last 5 years, with exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin.~Note: The presence of pathological involvement of axillary nodes will be assessed and agreed upon by two investigators.~Exclusion Criteria:~* Pregnancy or unwillingness to use a reliable contraceptive method in women of child-bearing potential.~* Severe underlying chronic illness or disease.~* Cardiomyopathy or baseline LVEF less than 50%.~* Other investigational drugs while on study.~* Severe or uncontrolled hypertension, history of congestive heart failure or severe coronary arterial disease.~* Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Subjects with ulcerative colitis are also excluded~* Taking any lapatinib-prohibited medication within 7 days of first dose of study medications. (See Prohibited Medications List in protocol.)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Single Group Assignment (Type: EXPERIMENTAL): Lapatinib Trastuzumab Endocrine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patient with established moderate to severe rheumatoid arthritis~Exclusion Criteria:~* All concomitant diseases or pathological conditions that could interfere and impact the assessment of the study treatment~* Previous clinical trials and previous biological therapy that could interfere with the results in the present clinical trials

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Certolizumab pegol (CZP) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improving Control and Reducing the Risk of Hypoglycemic Episodes in Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Have type 1 diabetes as defined by the American Diabetes Association or by the judgment of the physician~* Willing to participate for up to one year~* Perform routine blood glucose checks 3-4 times a day~* Complete monthly diaries of the occurrence of severe and moderate hypoglycemic episodes~* Have 6 hemoglobin A1c (HgbA1c) drawn~* Have a mixed meal tolerance test to assess for residual pancreatic insulin secretion~Exclusion Criteria:~* Age \< 18 years~* Currently abusing alcohol or drugs~* Severe depression or psychosis~* Significant mental impairment~* Inability to use a glucometer and a hand held computer~* Pregnant or desire to achieve pregnancy within the following year (females)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A Order: SMBG, IBMF-1, IBMF-2 (Type: EXPERIMENTAL): Group A performed routine self-monitored blood glucose (SMBG) alone (level 1), followed sequentially by Integrated Biobehavioral Monitoring \& Feedback - 1 (IBMF-1) level 2 and Integrated Biobehavioral Monitoring \& Feedback - 2 (IBMF-2) level 3. Each level continued for 3 months.
- Group B Order: IBMF-1, IBMF-2, SMBG (Type: EXPERIMENTAL): Group B began with Integrated Biobehavioral Monitoring \& Feedback - 1 (IBMF-1) level 2, followed by level 3, Integrated Biobehavioral Monitoring \& Feedback - 2 (IBMF-2) and then level 1 (SMBG only). Each level continued for 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed metastatic malignant melanoma that is considered unresectable~  * Stage III or IV ocular, mucosal, or cutaneous melanoma~* Measurable disease~* No CNS disease (phase I only)~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 70-100%~Life expectancy:~* Not specified~Hematopoietic:~* Absolute granulocyte count at least 1,500/mm\^3~* Platelet count at least 150,000/mm\^3~Hepatic:~* Bilirubin no greater than 1.5 times upper limit of normal (ULN)~* SGOT/SGPT no greater than 3 times ULN~* Alkaline phosphatase no greater than 3 times ULN~Renal:~* Creatinine no greater than 1.5 times ULN~Cardiovascular:~* No history of active angina~* No myocardial infarction within past 6 months~* No history of significant ventricular arrhythmia requiring medication with antiarrhythmics~Other:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective barrier contraception during and for 4 weeks before and after study~* No frequent vomiting or medical condition that could interfere with oral medication intake (e.g., partial bowel obstruction)~* No preexisting neurotoxicity grade 2 or greater~* No serious concurrent infections treated with antibiotics~* No nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the complications of this study~* No psychiatric disorders that would preclude study compliance~* No other medical condition or reason that would preclude study~* No other malignancy within the past 2 years except:~  * Nonmelanoma skin cancer~ * Carcinoma in situ of the cervix~ * History of T1a or b prostate cancer detected incidentally at TURP and comprising less than 5% of resected tissue with PSA normal since TURP~* No AIDS related illness~* HIV negative~PRIOR CONCURRENT THERAPY:~* Recovered from prior therapy~Biologic therapy:~* At least 4 weeks since prior biologic therapy~* At least 4 weeks since prior immunotherapy~* No concurrent immunotherapy~Chemotherapy:~* No prior systemic chemotherapy for metastatic melanoma~* No other concurrent chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* At least 4 weeks since prior radiotherapy, interstitial brachytherapy, or radiosurgery~* At least 3 weeks since prior radiotherapy to the brain if brain metastases from melanoma~* Prior radiotherapy to only indicator lesion allowed provided recent evidence of disease progression at that site~* No concurrent radiotherapy~Surgery:~* At least 2 weeks since prior surgery requiring general anesthesia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Memantine - Communication Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatient at least 50 years of age and at least 8 years of education.~* The patient should have German as a mother-tongue or at least speak the language fluently in order to achieve similar scores in verbal tasks.~* Current diagnosis of probable Alzheimer's disease consistent with NINCDS- ADRDA criteria or with DSM IV TR criteria for Dementia of the Alzheimer's type.~* Mini Mental State Examination (MMSE) total score is less than 20~* Patients treated with any acetylcholinesterase inhibitor (AChEI) may be included, when treatment has started at least 6 months prior screening and was stable during the last 3 months.~Exclusion Criteria:~* Any type of evident aphasia, which may interfere with patient's communication difficulties caused by Alzheimer's disease~* History of severe drug allergy, or hypersensitivity, or patients with known hypersensitivity to amantadine, lactose.~* Evidence (including CT/MRI results) of any clinically significant central nervous system disease other than Alzheimer's disease.~* Modified Hachinski Ischemia score greater than 4 at screening.~* Current evidence of clinically significant systemic disease~* Known or suspected history of alcoholism or drug abuse within the past 10 years.~* Previous treatment with memantine or participation in an investigational study with memantine.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Integrating DR Into Mainstream Health System in Bangladesh

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* atleast 18 years of age~* Persons with diabetes who are registered with Barishal Diabetes Hospital~* Referred to SBMC\&H (tertiary hospital) for DR management (screening/treatment), from September 2017 - August 2018~* Persons who did not undergo a Dilated Fundus Examination (DFE) in last 12 months~* those who provide informed consent to be included in this study~Exclusion Criteria:~* Below 18 years of age~* Persons with diabetes who are registered with Barishal Diabetes Hospital but not referred to SBMC\&H (tertiary hospital) for DR management~* Persons with diabetes referred to SBMC\&H before September 2017 or after August 2018~* Persons who have undergone a Dilated Fundus Examination (DFE) in last 12 months~* those who do not provide informed consent to be included in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Health Education Intervention (Type: EXPERIMENTAL): Face-to-face health education session on Diabetic Retinopathy and available services at a tertiary hospital, followed by telephonic reminders at Day 7, 30 and 90.
- Control Group (Type: NO_INTERVENTION): No Intervention will be conducted in this control group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Caucasian; male or female outpatients and age between 18-80 years of age, inclusive.~* Patients with a history of essential hypertension and who are actually treated either with an antihypertensive monotherapy and with a diastolic blood pressure \>=90 and \<= 105mmHg or with a combination therapy (limited to two active compounds) and with a diastolic blood pressure of \>=90 and \<= 100mmHg.~* Patients with Left Ventricular Hypertrophy~Exclusion Criteria:~* Severe hypertension~* Symptomatic heart failure~* History of stroke, heart attack, coronary bypass surgery etc.~* Insulin-dependent diabetes mellitus or poorly controlled diabetes mellitus.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Amlodipine + Valsartan (Type: EXPERIMENTAL): Participants received 160 mg Valsartan and 5 mg amlodipine orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to valsartan/amlodipine 160/10 mg. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication.
- Losartan + Hydrochlorothiazide (Type: ACTIVE_COMPARATOR): Participants received 100 mg losartan and 12.5 mg Hydrochlorothiazide (HCT) orally once a day for 52 weeks. If blood pressure was not normalized at week 4, treatment was uptitrated to losartan/HCT 100/25 mg, respectively, until end of study. Participants with still uncontrolled hypertension could receive add-on antihypertensive medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: GIP Receptor Antagonist Studies in Humans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Normal kidney function, liver function and hemoglobin levels.~Exclusion Criteria:~* Medication, Diabetes type 1 or 2, BMI \> 25, first degree relatives with Type 2 Diabetes

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Infusion of saline
- GIP(1-42) (Type: ACTIVE_COMPARATOR): Infusion of agonist, GIP(1-42)
- GIP-A (Type: EXPERIMENTAL): Infusion of GIP-A alone
- GIP-A + GIP(1-42) (Type: EXPERIMENTAL): Infusion of GIP-A and GIP(1-42)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Primary Inclusion Criteria:~* Health care professional (eg, physician, osteopath, nurse, pharmacist)~* 18 years of age or older~* Enrolled or enrolling in an extended outpatient treatment program for opioid dependence~* Women of childbearing potential must agree to use an approved method of contraception for the duration of the study~Primary Exclusion Criteria:~* Pregnancy and/or lactation~* Evidence of hepatic failure~* Active hepatitis~* Any psychiatric disorder that would compromise ability to complete study requirements~* Recent history of suicidal ideation or attempt~* Current dependence to any drugs other than prescription opioids or heroin, benzodiazepines, caffeine, marijuana, alcohol, or nicotine~* Positive urine drug test or self-reported use of opioids, cocaine, or amphetamines at screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Medisorb naltrexone 380 mg (VIVITROL) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Safety and Immunogenicity of the Bivalent Killed Whole Cell Oral Cholera Vaccine in Adults and Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female adults aged 18-40 years and children aged 1 -17 years who the investigator believes will comply with the requirements of the protocol (i.e. available for follow-up visits and specimen collection).~2. For females of reproductive age, they must not be pregnant (as determined by verbal screening).~3. Written informed consent obtained from the subjects or their parents/guardians, and written assent for children aged 12 - 17 years.~4. Healthy subjects as determined by: Medical history, Physical examination, Clinical judgment of the investigator~Exclusion Criteria:~1. Ongoing serious chronic disease~2. Immunocompromising condition or therapy~3. Diarrhea (3 or more loose/more watery stools within a 24-hour period) 6 weeks prior to enrollment~4. One or two episodes of diarrhea lasting for more than 2 weeks in the past 6 months~5. One or two episodes of abdominal pain lasting for more than 2 weeks in the past 6 months~6. Intake of any anti-diarrhea medicine in the past week~7. Abdominal pain or cramps, loss of appetite, nausea, general ill-feeling or vomiting in the past 24 hours~8. Acute disease one week prior to enrollment, with or without fever. Temperature ≥38ºC (oral) or axillary temperature ≥ 37.5ºC warrants deferral of the vaccination pending recovery of the subject~9. Receipt of antibiotics in past 14 days~10. Receipt of live or killed enteric vaccine in past 4 weeks~11. Receipt of killed oral cholera vaccine

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Vaccine (Type: EXPERIMENTAL): killed bivalent (O1 and O139)whole cell oral cholera vaccine(Shanchol™)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* The subject has a history of inadequate response to at least 1, but no more than 4, of the following DMARDs: sulfasalazine, injectable gold, methotrexate, leflunomide, cyclosporine, or a thiopurine derivative (azathioprine or 6-mercaptopurine)~Exclusion Criteria:~* Current Therapy With Any DMARD Or Biologic

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 5 mg BID (Type: EXPERIMENTAL): CP 690,550 5 mg BID
- 15 mg BID (Type: EXPERIMENTAL): CP 690,550 15 mg BID
- 30 mg BID (Type: EXPERIMENTAL): Oral tablets administered at a dose of 30 mg BID for 6 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study on the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia During Concurrent Chemoradiotherapy of Cervical Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-70 years old;~* Patients with cervical cancer who have not undergone surgery for initial treatment, the international union of gynecology and obstetrics (FIGO) stage IIb-IIIb; Squamous cell carcinoma diagnosed by histopathology.~* The expected survival time was more than 8 months; the Eastern Cooperative Oncology Group (ECOG) performance status score≤1;~* Bone marrow hematopoietic function is normal before treatment (ANC≥1.8×109/L, PLT≥100×109/L, Hb≥90g/L, WBC≥4.0×109/L);~* No obvious abnormality in the ECG examination, and no obvious cardiac dysfunction;~* All patients must agree to take effective contraceptive measures during the study period and within 6 months after stopping treatment, and women of childbearing age must have a negative urine pregnancy test prior to treatment administration;~* The subjects voluntarily participate in this clinical trial and sign an informed consent form.~Exclusion Criteria:~* Those who refuse to accept PEG-rh-G-CSF;~* Currently conducting clinical trials of other drugs;~* Uncontrolled infection before treatment, body temperature ≥ 38℃;~* Chronic diseases of the heart, kidney, liver or other important organs;~* Patients with severe uncontrolled diabetes;~* Pregnant or lactating female patients;~* Persons with allergic diseases or allergic constitution, or allergic to this product or other biological products derived from genetically engineered E. coli;~* Suspected or confirmed drug, substance or alcohol abuse;~* Severe mental or neurological disorders that affect informed consent and/or adverse reaction presentation or observation;~* HIV-positive people;~* Patients requiring radiation therapy for the retroperitoneal or inguinal region.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- experimental group (Type: EXPERIMENTAL): patients used 6 mg PEG-rhG-CSF prophylactically after chemotherapy
- control group (Type: PLACEBO_COMPARATOR): patients did not use PEG-rhG-CSF for prevention and were given 5 ug/kg rhG-CSF when ANC\<1✕109/L

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete